Alpha2-Selective Digoxin Derivatives for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, which focus on controlling intra-ocular pressure, often require surgical intervention due to uncontrolled pressure despite available drugs, and existing cardiac glycosides like digoxin have systemic toxicity issues.
Innovation Solution
Development of digoxin derivatives that are selective inhibitors of the α2 isoform of Na,K-ATPase, specifically modified to increase selectivity for the α2 isoform, reducing intra-ocular pressure and potentially offering a safer cardiotonic effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If digoxin is used to inhibit Na,K-ATPase to reduce intra-ocular pressure, then IOP control is achieved, but systemic toxicity occurs
Solution Approach 1:
The patent modifies the sugar moiety of digoxin to create derivatives with selective affinity for the α2 isoform of Na,K-ATPase, which is locally expressed in the ciliary epithelium of the eye. This local selectivity allows the drug to target ocular tissue specifically while minimizing interaction with other Na,K-ATPase isoforms in systemic tissues, thereby reducing systemic toxicity while maintaining IOP control efficacy.
Solution Approach 2:
The patent chemically modifies the sugar portion of the digoxin molecule to alter its binding characteristics. By changing the chemical parameters of the sugar moiety, the drug achieves selective inhibition of the α2 isoform in the ciliary epithelium while having reduced affinity for other isoforms, thus resolving the contradiction between effective IOP control and systemic toxicity.
2Object-affected harmful factors
If topical administration is used to minimize systemic side-effects, then systemic toxicity is reduced, but drug penetration through the cornea must be effective
Solution Approach 1:
The patent designs the digoxin derivative to have specific physicochemical properties that enable effective penetration through the corneal barrier while maintaining selectivity for the α2 isoform in the ciliary epithelium. The modified sugar moiety provides both the necessary penetration characteristics and the selective binding affinity, allowing topical administration to effectively reach the target tissue with minimal systemic absorption.
3Object-affected harmful factors
If α2-selective cardiac glycosides are developed to reduce cardiotoxicity, then cardiac safety is improved, but selectivity for α2 isoform must be maintained
Solution Approach 1:
The patent systematically modifies the sugar moiety of digoxin to create derivatives with optimized binding parameters for the α2 isoform. By precisely adjusting the chemical structure of the sugar portion, the patent achieves high selectivity for α2 while reducing affinity for α1 and α3 isoforms, thereby minimizing cardiotoxicity associated with non-selective inhibition.
Solution Approach 2:
The patent focuses modifications specifically on the sugar moiety segment of the digoxin molecule, leaving the aglycone portion unchanged. This segmented approach allows selective modification of binding characteristics without affecting the core cardiotonic activity, enabling precise control over isoform selectivity and cardiac safety.
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present invention relates to digoxin and digitoxin derivatives that are selective inhibitors of the α2 isoform of Na,K-ATPase, and that reduce intra-ocular pressure. The invention further relates to uses of these derivatives for treating disorders associated with elevated intraocular pressure, such as glaucomas, and/or as cardiotonic agents.